7 天前 - … The relative efficacy of risankizumab and ustekinumab in inflammatory bowel
disease … patients whose disease was refractory to anti-TNF therapy. Our trial also evaluated …

17 天前 - … Anti-TNF agents are human IgG1 monoclonal antibodies that … of CD due to a lack
of treatment response. A Cochrane … of vedolizumab in inflammatory bowel disease: A national …

23 天前 - … therapy to anti‐TNF monotherapy in children with IBD. … We evaluated whether
IMM withdrawal impacts laboratory … duration of therapeutic response.The risks of combination …

28 天前 - … At the age of 37, he sought an evaluation from the … already described in inflammatory
bowel disease–arthritis (7). … symptoms in HS patients undergoing anti-TNF treatment. …

32 天前 - … We evaluated this hypothesis by following a targeted … and compromised treatment
response to an anti-TNF treated … Ulcerative colitis (UC) is an inflammatory bowel disease (IBD…

41 天前 - … for response to remission induction treatment with anti-TNF … Inflammatory bowel
diseases such as UC pose a heavy … treatment response [28,29] in light of clinical outcomes and …

49 天前 - … : (Crohn's Disease) OR (Inflammatory Bowel Disease) … that the treatment with
anti-TNF works better in patients with … may even have a correlation with treatment response [52]. …

53 天前 - … bowel disease (IBD), most commonly in patients with … survey to those attending clinic
in July 2023 to evaluate satisfaction … were paradoxical secondary to anti-TNF therapy. Most …

53 天前 - … CI 33.6–40.5%) of anti-TNF failed CD patients treated with vedolizumab after TNF
failure… (QoL) are treatment targets for pts with CD. We evaluated the PRO2 and QoL response …

53 天前 - … on treatment. The microbiome was evaluated before and after starting biologic
therapy, … ), conventional treatment, and inflammatory bowel disease (IBD) patients. A descriptive …